NCT02845050撤回1 期
Phase Ib/II Study Assessing the Neo-adjuvant Combination Therapy of Vinflunine With Cisplatin Followed by Radical Cystectomy in Patients With Muscle-invasive Bladder Cancer (JaNEO)
Ligartis GmbH2 个研究点 分布在 1 个国家开始时间: 2016年7月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 发起方
- 试验地点
- 2
- 主要终点
- Pathological Complete Response (pCR)
研究概览
简要总结
Phase Ib/II study assessing the neo-adjuvant combination therapy of vinflunine with cisplatin followed by radical cystectomy in patients with muscle-invasive bladder cancer (JaNEO).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients aged ≥ 18 years and ≤ 75 years with legal capacity
- •Signed written informed consent
- •Histologically confirmed muscle-invasive urothelial cell carcinoma of the bladder (MIBC) with clinical T2-T4a (N0/Nx, M0) assessed by primary PDD-guided TUR-B and by the screening imaging (MRI pelvis and CT chest/abdomen) which both must include the use of contrast medium
- •Confirmed adequate complete resection of all visible tumor during TUR-B according to current treatment guidelines before registration; the latest TUR-B must have been done ≤ 8 weeks before registration
- •ECOG performance status of 0 or 1
- •Adequate bone marrow, renal and hepatic functions as evidenced by the following:
- •Absolute Neutrophil Count ≥ 2,000 mm3 and ≤ 7,500 mm3
- •Hemoglobin ≥ 12 g/dL for the safety phase of the study; if the study treatment proved to be adequate tolerated during this safety phase, the threshold can be lowered to ≥ 10 g/dL according to the decision of the study steering committee
- •Platelet count ≥ 100,000 mm3
- •Serum albumin within normal range
- •Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN)
- •Transaminases (ALT, AST) ≤ 1.5 x ULN
- •Creatinine clearance ≥ 60 mL/min, calculated based on a 24h-measured creatinine clearance
- •Serum Urea < 25 mg/100 ml
- •Absence of psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; these conditions should be assessed with the patient before registration
- •Electrocardiogram (ECG) without modifications that suggest a high risk of occurrence of an acute clinical event (such as signs of angina pectoris or high-risk arrhythmia, etc.); cardiologist consultation is required, if relevant abnormalities are observed in the screening ECG-assessment
排除标准
- •Prior systemic chemotherapy for any kind of malignancy; prior intravesical chemotherapy or treatment with BCG is allowed
- •Prior radiation of the pelvis or any prior radiation to ≥ 30 % of the bone marrow
- •Evidence of lymph node (N+) or distant metastasis (M1) in the screening imaging assessment, including known brain metastases or leptomeningeal involvement (however, brain-MRI-scans are not required to rule out CNS-involvement, unless there is clinical suspicion of central nervous system (CNS) disease)
- •Any contraindication with regard to contrasted imaging (MRI or CT)
- •Other malignancies except adequately treated basal carcinoma of the skin, localized prostate cancer Gleason ≤ 6, in-situ cervix carcinoma or any other tumor with a disease free interval ≥ 5 years
- •Peripheral neuropathy Grade ≥ 2 NCI CTCAE v4.03 or hearing impairment Grade ≥ 2 NCI CTCAE v.4.03
- •Any concurrent chronic system immune therapy or previous organ allograft
- •Weight loss > 5 % within the last 3 months before registration
- •Any other serious illness or medical condition including:
- •Infection requiring systemic anti-infective therapy within the last 2 weeks before registration
- •History of cardio-vascular disease that might compromise the safe administration of cisplatin
- •Dehydration requiring IV fluid substitution
- •Any medical condition that might not be controlled, e.g. patients with unstable angina pectoris, myocardial infarction < 6 months before registration or uncontrolled diabetes, congestive cardiac failure > NYHA grade I
- •Known hypersensitivity to the study drugs or to drugs with similar chemical structures
- •Treatment with any potent CYP3A4 inhibitor or inductor (e.g. ketoconazole, itraconazole, ritonavir, amprenavir, indinavir, rifampicine) or phenytoine; replacement of such treatment with alternative treatment options before start of study treatment is acceptable, if medically feasible and ethically acceptable
- •Treatment with any medication that is known to prolong the QT/QTc interval and/or to cause Torsades de Pointes (e.g. azithromycine, amitryptiline, imipramine, clozapine, flu-ox¬etine, cisapride); replacement of such treatment with alter¬na¬ti¬ve options before start of study treatment is acceptable, if medically feasible and ethically acceptable
- •Treatment with hexamethylmelamin, pyridoxine, penicillamine or any other drug with known potential to affect the efficacy of cisplatin
- •Treatment with any other investigational or anti-cancer therapy ≤ 30 days before registration
- •Pregnant or lactating female patients or female patients of childbearing potential with positive pregnancy test at screening
- •Women of child-bearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 6 months after the study
- •Sexually active fertile men, who are unwilling or unable to use an effective birth control from day of informed consent and for up to 6 months after the last cycle of chemotherapy, if their partners are women of child-bearing potential (if cystectomy is not performed) effective birth control means the use of condoms ideally combined with any acceptable contraception of the male patient's partner as described in exclusion criterion 16
研究组 & 干预措施
Vinflunine+Cisplatin+radical cystectomy
Experimental
neoadjuvant combination of Vinflunine+Cisplatin before radical cystectomy as proof of principle (one arm only!)
干预措施: Vinflunine (Drug)
Vinflunine+Cisplatin+radical cystectomy
Experimental
neoadjuvant combination of Vinflunine+Cisplatin before radical cystectomy as proof of principle (one arm only!)
干预措施: Cisplatin (Drug)
Vinflunine+Cisplatin+radical cystectomy
Experimental
neoadjuvant combination of Vinflunine+Cisplatin before radical cystectomy as proof of principle (one arm only!)
干预措施: Radical cystectomy (Procedure)
结局指标
主要结局
Pathological Complete Response (pCR)
时间窗: cystectomy
Rate of pathological complete response (pCR) at cystectomy assessed by central pathological review (Prof. Hartmann, Erlangen), if the initial safety phase allows continuation of the trial with the phase II part
次要结局
- Overall radiological response rate before cystectomy(prior cystectomy)
- Progression rate(after 2 and 4 cycles (of 21 days length) of treatment)
- Safety of chemotherapy measured by adverse events and clavien-dindo grades(through study completion after 12 months-follow up)
- Rate of complications at cystectomy(at cystectomy)
- Perioperative morbidity/mortality(30 days and 90 days post surgery)
- Cancer-specific survival(one year after cystectomy)
- QoL - GIQLI(Cycle 1-4 Day 1+ cystectomy + 1,3 and 12 months after cystectomy)
- QoL - QLQ-C30(Cycle 1-4 Day 1+ cystectomy + 1,3 and 12 months after cystectomy)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
2 期
A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaNCT06444009Lei Liu90
尚未招募
2 期
Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell CarcinomaRenal Cell CarcinomaNCT06129955Sun Yat-sen University47
终止
2 期
Cisplatin and Nab-paclitaxel for (N2) Defined NSCLCStage IIIA Non-Small Cell Lung CancerNCT02276560UNC Lineberger Comprehensive Cancer Center1
已完成
2 期
Postoperative Chemoradiotherapy With S-1 in Gastric CancerGastric CancerNCT01824004Chonnam National University Hospital46
已完成
3 期
Adjuvant Vinorelbine Plus Cisplatin(NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer(NSCLC)Non-small Cell Lung CancerNCT01124253Shanghai Jiao Tong University School of Medicine250